Cervical Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CRV031 MIFTS: 48	Cervical Adenocarcinoma Categories: Cancer diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Cervical Adenocarcinoma

MalaCards integrated aliases for Cervical Adenocarcinoma:

Name: Cervical Adenocarcinoma ¹¹ ⁵⁸ ⁵³ ¹⁴ ¹⁶ ⁷¹

Adenocarcinoma of the Uterine Cervix ¹¹

Adenocarcinoma of the Cervix Uteri ⁵⁸

Adenocarcinoma Cervix Uteri ¹¹

Adenocarcinoma of Cervix ¹¹

Characteristics:

Prevelance:

Adenocarcinoma of the Cervix Uteri: 1-9/100000 (Europe, Bulgaria, Czech Republic, Iceland, Lithuania, Norway, Portugal, Slovakia, Slovenia) 1-9/1000000 (Austria, Belgium, Croatia, Estonia, Finland, Germany, Ireland, Italy, Latvia, Malta, Poland, Spain, Switzerland, Netherlands, United Kingdom) ⁵⁸

Age Of Onset:

Adenocarcinoma of the Cervix Uteri: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of cervix uteri

Malignant neoplasm: Endocervix

Malignant neoplasm: Exocervix

Malignant neoplasm: Overlapping lesion of cervix uteri

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of female genital organs

Malignant neoplasms of cervix uteri

Adenocarcinoma of cervix uteri

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹¹ DOID:3702

NCIt ⁴⁹ C4029

SNOMED-CT ⁶⁸ 254887002

ICD10 via Orphanet ³² C53.0 C53.1 C53.8

UMLS via Orphanet ⁷² C0279672

Orphanet ⁵⁸ ORPHA213772

EFO ¹⁶ EFO_0001416

ICD11 ³³ 261293318

UMLS ⁷¹ C0279672

Sources

Summaries for Cervical Adenocarcinoma

Disease Ontology: ¹¹ A cervix carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Cervical Adenocarcinoma, also known as adenocarcinoma of the uterine cervix, is related to cervical clear cell adenocarcinoma and cervical mucinous adenocarcinoma. An important gene associated with Cervical Adenocarcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Signal Transduction and Signaling by Receptor Tyrosine Kinases. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include cervix, lymph node and endothelial, and related phenotypes are neoplasm and normal

Sources

Related Diseases for Cervical Adenocarcinoma

Diseases in the Cervical Adenocarcinoma family:

Early Invasive Cervical Adenocarcinoma

Diseases related to Cervical Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 612)

#	Related Disease	Score	Top Affiliating Genes
1	cervical clear cell adenocarcinoma	32.2	KRT7 CDKN2A
2	cervical mucinous adenocarcinoma	32.1	PGR KRT7 CDKN2A
3	cervical serous adenocarcinoma	32.1	PGR CEACAM5
4	adenocarcinoma	31.4	TP53 KRT7 KRT20 KRAS CXCL12 CEACAM5
5	adenocarcinoma in situ	31.4	TP53 KRT7 KRAS CEACAM5 CDX2 CDKN2A
6	suppressor of tumorigenicity 3	31.3	TP53 CDKN2A CDKN1A
7	cervical squamous cell carcinoma	30.8	TP53 RASSF1 MKI67 KRAS CEACAM5 CDKN2A
8	endocervical adenocarcinoma	30.8	TP53 PGR KRT7 ESR1 CEACAM5 CDKN2A
9	adenosquamous carcinoma	30.8	PGR NME1 KRT7 KRT20 KRAS CEACAM7
10	papillary transitional carcinoma	30.7	TP53 KRT7 KRT20
11	hepatoid adenocarcinoma	30.7	KRT7 CEACAM5 CDX2
12	cervical cancer	30.7	TP53 RASSF1 NME1 EBAG9 CDKN2A CDKN1A
13	papillary serous adenocarcinoma	30.7	TP53 PGR KRT7 KRAS ESR1 CEACAM5
14	papilloma	30.7	TP53 RASSF1 KRT7 KRT20 KRAS CDKN2A
15	signet ring cell adenocarcinoma	30.6	TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
16	bilateral breast cancer	30.5	TP53 PGR ESR1 CDKN2A
17	appendix adenocarcinoma	30.5	TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
18	pancreatic adenocarcinoma	30.5	TP53 KRAS CXCL12 CDKN2A CDKN1A
19	vulval paget's disease	30.4	KRT7 CEACAM5 CDKN2A
20	vaginal cancer	30.4	TP53 PGR KRT7 ESR1 CDKN2A
21	ovarian cystadenocarcinoma	30.4	TP53 KRAS ESR1 CEACAM5 CDKN2A
22	squamous cell carcinoma	30.4	TP53 NME1 MKI67 LAMC2 KRT7 KRAS
23	mucinous cystadenocarcinoma	30.4	KRT7 KRT20 KRAS CEACAM7 CEACAM5 CDX2
24	rectal benign neoplasm	30.4	TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
25	mucinous adenocarcinoma	30.4	TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
26	rectum cancer	30.3	TP53 KRT20 KRAS CEACAM7 CEACAM5 CDKN1A
27	small cell carcinoma	30.3	TP53 KRT7 KRT20 CEACAM5
28	transitional cell carcinoma	30.3	TP53 NME1 MKI67 KRT7 KRT20 CDKN1A
29	cystadenocarcinoma	30.3	TP53 PGR KRT7 KRAS CEACAM5 CDKN1A
30	serous cystadenocarcinoma	30.3	TP53 PGR KRT7 KRAS ESR1 CDKN2A
31	neuroendocrine carcinoma	30.3	PGR KRT7 KRT20 ESR1
32	cystitis	30.3	TP53 KRT7 KRT20
33	breast lobular carcinoma	30.2	TP53 PGR KRT7 ESR1
34	leiomyoma	30.2	TP53 PGR MKI67 ESR1
35	vaginal discharge	30.2	PGR KRT7 ESR1 CEACAM5
36	adenoid squamous cell carcinoma	30.2	TP53 KRT7 CEACAM5
37	large cell neuroendocrine carcinoma	30.2	TP53 KRT7 KRAS
38	breast fibroadenoma	30.2	TP53 RASSF1 PGR NME1 MKI67 ESR1
39	cervix endometriosis	30.2	CDKN2A CALB2
40	endometrial adenocarcinoma	30.2	TP53 PGR KRT7 KRAS ESR1 CDKN2A
41	cervical polyp	30.2	PGR ESR1
42	ovary adenocarcinoma	30.1	TP53 PGR KRT7 KRAS ESR1 CEACAM5
43	mammary paget's disease	30.1	PGR KRT7 KRT20 ESR1 CEACAM5
44	intestinal obstruction	30.1	KRT7 KRT20 CEACAM5 CDX2
45	cervix carcinoma	30.1	TP53 PGR KRT7 KRAS ESR1 CEACAM5
46	human papillomavirus infectious disease	30.1	TP53 CDKN2A CDKN1A
47	vulva cancer	30.1	TP53 KRT7 CEACAM5 CDKN2A
48	adenomyoma	30.0	PGR KRT7 ESR1 CDKN2A
49	uterine carcinosarcoma	30.0	TP53 KRAS ESR1
50	adenoma	30.0	TP53 MKI67 KRT7 KRT20 KRAS CDX2

Graphical network of the top 20 diseases related to Cervical Adenocarcinoma:

Sources

Symptoms & Phenotypes for Cervical Adenocarcinoma

GenomeRNAi Phenotypes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.15	CALB2 CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7
2	no effect	GR00402-S-2	10.15	CALB2 CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7

MGI Mouse Phenotypes related to Cervical Adenocarcinoma:

⁴⁵ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.31	CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
2	normal	MP:0002873	10.22	CALB2 CDX2 CEACAM7 CXCL12 ESR1 KRAS
3	cellular	MP:0005384	10.18	CDKN1A CDKN2A CDX2 CEACAM5 CXCL12 CXCR4
4	endocrine/exocrine gland	MP:0005379	10.17	CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
5	muscle	MP:0005369	10.15	CDKN1A CDKN2A CEACAM5 CXCL12 CXCR4 ESR1
6	no phenotypic analysis	MP:0003012	10.11	CDKN1A CDKN2A CXCL12 ESR1 KRAS MKI67
7	digestive/alimentary	MP:0005381	10.1	CDKN1A CDKN2A CDX2 CEACAM5 CXCR4 ESR1
8	immune system	MP:0005387	10.1	CDKN1A CDKN2A CEACAM5 CEACAM7 CXCL12 CXCR4
9	liver/biliary system	MP:0005370	10.08	CDKN1A CDKN2A CXCL12 ESR1 KRAS NME1
10	cardiovascular system	MP:0005385	10.06	CDKN1A CDKN2A CDX2 CEACAM5 CXCL12 CXCR4
11	limbs/digits/tail	MP:0005371	10	CDKN1A CDX2 ESR1 KRAS LAMC2 PGR
12	skeleton	MP:0005390	9.85	CDKN1A CDKN2A CDX2 CEACAM7 CXCR4 ESR1
13	mortality/aging	MP:0010768	9.8	CDKN1A CDKN2A CDX2 CEACAM5 CEACAM7 CXCL12
14	integument	MP:0010771	9.32	CDKN1A CDKN2A CEACAM7 CXCR4 ESR1 KRAS

Sources

Drugs & Therapeutics for Cervical Adenocarcinoma

Drugs for Cervical Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

Topotecan

Approved, Investigational

Phase 3

123948-87-8, 119413-54-6

60699 60700

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Tirapazamine

Investigational

Phase 3

27314-97-2

135413511

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Antimetabolites

Phase 3

Albumin-Bound Paclitaxel

Phase 3

Antimitotic Agents

Phase 3

Tubulin Modulators

Phase 3

topoisomerase I inhibitors

Phase 3

Epoetin Alfa

Phase 3

Hematinics

Phase 3

Chrysarobin

Phase 3

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Vaccines

Phase 3

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Ipilimumab

Approved

Phase 2

477202-00-9

Nivolumab

Approved

Phase 2

946414-94-4

D-Tyrosine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

133585-56-5, 60-18-4, 556-02-5

1153 6057

Veliparib

Investigational

Phase 2

912444-00-9

11960529

Immunoglobulins, Intravenous

Phase 2

Immunoglobulin G

Phase 2

Antibodies, Monoclonal

Phase 2

Fluorodeoxyglucose F18

Phase 1, Phase 2

Angiogenesis Inhibitors

Phase 2

Endothelial Growth Factors

Phase 2

Mitogens

Phase 2

Protein Kinase Inhibitors

Phase 2

Anti-Bacterial Agents

Phase 2

Antifungal Agents

Phase 2

Antibiotics, Antitubercular

Phase 2

Adjuvants, Immunologic

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Immunoglobulins

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Interventional clinical trials:

(show top 50) (show all 54)

#	Name	Status	NCT ID	Phase	Drugs
1	A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix	Completed	NCT00803062	Phase 3	Cisplatin;Paclitaxel;Topotecan Hydrochloride
2	Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer	Completed	NCT00017004	Phase 3	Cisplatin
3	A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix	Completed	NCT00064077	Phase 3	Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4	A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial	Completed	NCT01414608	Phase 3	Carboplatin;Cisplatin;Paclitaxel
5	Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)	Active, not recruiting	NCT01101451	Phase 3	Cisplatin
6	A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer	Active, not recruiting	NCT02466971	Phase 3	Cisplatin;Triapine
7	A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years	Active, not recruiting	NCT03493542	Phase 3
8	A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis	Terminated	NCT00262821	Phase 3	cisplatin;tirapazamine
9	A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA	Completed	NCT00369122	Phase 2	Cisplatin
10	A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies	Completed	NCT01693783	Phase 2
11	A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer	Completed	NCT00559377	Phase 2
12	A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study	Completed	NCT02562729	Phase 2
13	Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage	Completed	NCT00416455	Phase 1, Phase 2	ferumoxtran-10
14	A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma	Completed	NCT00389974	Phase 2	sunitinib malate
15	A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix	Completed	NCT00039442	Phase 2	Capecitabine
16	A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer	Completed	NCT00057863	Phase 2	Paclitaxel;Oxaliplatin
17	Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer	Completed	NCT00217633	Phase 2
18	A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix	Completed	NCT00309959	Phase 2	Paclitaxel Albumin-Stabilized Nanoparticle Formulation
19	A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix	Completed	NCT01026792	Phase 2	Temsirolimus
20	A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix	Completed	NCT01266460	Phase 2
21	A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix	Completed	NCT01266447	Phase 2	Topotecan Hydrochloride;Veliparib
22	A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048)	Completed	NCT01267253	Phase 2	Brivanib Alaninate
23	A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer	Completed	NCT02921269	Phase 2	Atezolizumab
24	PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX	Completed	NCT02164461	Phase 1, Phase 2
25	A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer	Completed	NCT02880007	Phase 2	Cisplatin
26	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
27	A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer	Active, not recruiting	NCT02257528	Phase 2
28	Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma: A Phase II Single-arm Clinical Study	Not yet recruiting	NCT05259540	Phase 2	compound kushen injection combined with pabolizumab
29	A Phase II Clinical Trial of Ixabepilone (Ixempra [R], BMS-247550, NSC 710428), an Epothilone B Analog, in Cervical Cancer	Terminated	NCT00924066	Phase 2	Ixempra (Ixabepilone (BMS-247550) )
30	A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC)	Withdrawn	NCT03834571	Phase 2	Carboplatin;Cisplatin;Paclitaxel
31	A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes	Unknown status	NCT01295502	Phase 1	Carboplatin;Cisplatin;Paclitaxel
32	A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer	Completed	NCT00104910	Phase 1	Cisplatin
33	A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS	Completed	NCT00054444	Phase 1	Topotecan Hydrochloride Liposomes;Cisplatin
34	A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis	Completed	NCT00068549	Phase 1	Gemcitabine Hydrochloride;Cisplatin
35	A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix	Completed	NCT01281852	Phase 1	Cisplatin;Paclitaxel;Veliparib
36	A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes	Completed	NCT01711515	Phase 1	Cisplatin
37	Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer	Recruiting	NCT02595879	Phase 1	Cisplatin;Triapine
38	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Recruiting	NCT02020707	Phase 1	Nab-paclitaxel
39	Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer	Active, not recruiting	NCT03452332	Phase 1
40	Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer	Active, not recruiting	NCT03738228	Phase 1	Atezolizumab;Cisplatin
41	A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma	Unknown status	NCT03742869
42	Observational Study for Determine the Presence and Genotypes of HVP Infection in Cervical Intraepithelial Neoplasia Grade II-III (CIN II-III), and Stage I Cervical Epidermoid Carcinoma and Cervical Adenocarcinoma.	Completed	NCT00937547
43	Glycoprotein and Glycan Profiling in Patients With Locally Advanced Cervical Cancer (Stage IB2, IIA > 4 CM, IIB to IVA) Undergoing Pelvic and Para-aortic (Abdominal) Lymphadenectomy	Completed	NCT00460356
44	Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer	Completed	NCT00897442
45	Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer	Recruiting	NCT02140021
46	Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix - a Rare Tumor	Recruiting	NCT05046080
47	Yoga Therapy During Chemotherapy and Radiation Treatment for Local-Regional Cervical Cancer	Recruiting	NCT04622670
48	Clinical Evaluation Study of Urine hrHPV Detection for the Diagnosis of Presence of Cervical HPV and Correlation of Cervical Lesions	Recruiting	NCT05210348
49	MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix	Active, not recruiting	NCT01992861
50	Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (≤ 2CM) Cervical Cancer	Active, not recruiting	NCT01649089

Search NIH Clinical Center for Cervical Adenocarcinoma

Sources

Genetic Tests for Cervical Adenocarcinoma

Sources

Anatomical Context for Cervical Adenocarcinoma

Organs/tissues related to Cervical Adenocarcinoma:

MalaCards : Cervix, Lymph Node, Endothelial, Uterus, Breast, Lung, T Cells

Sources

Publications for Cervical Adenocarcinoma

Articles related to Cervical Adenocarcinoma:

(show top 50) (show all 1876)

#	Title	Authors	PMID	Year
1	P53 codon 72 and p21 codon 31 polymorphisms and susceptibility to cervical adenocarcinoma in Korean women. ⁵³ ⁶²	Roh JW...Kang SB	20524403	2010
2	Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. ⁵³ ⁶²	Muller S...Andersson S	18202755	2008
3	The biological role of the unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. ⁵³ ⁶²	Sonoda K...Wake N	17981616	2008
4	Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. ⁵³ ⁶²	McCluggage WG...McBride HA	18156982	2008
5	Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. ⁵³ ⁶²	Choi JS...Lee SK	17252195	2007
6	Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. ⁵³ ⁶²	Baalbergen A...Helmerhorst TJ	17354237	2007
7	Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. ⁵³ ⁶²	Kang S...Dong SM	17360030	2007
8	[Correlation of CXCR4/CXCL12 overexpression to lymph node metastasis and chronic inflammation in cervical adenocarcinoma]. ⁵³ ⁶²	Wei M...Li JQ	17355795	2007
9	Immunohistochemistry as a diagnostic aid in cervical pathology. ⁵³ ⁶²	McCluggage WG	17365826	2007
10	Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. ⁵³ ⁶²	Tsai CC...ChangChien CC	16290001	2006
11	Immunohistochemical characterization of endocervical papillary serous carcinoma. ⁵³ ⁶²	Nofech-Mozes S...Khalifa MA	16515605	2006
12	p16 expression in the female genital tract and its value in diagnosis. ⁵³ ⁶²	O'Neill CJ...McCluggage WG	16462152	2006
13	The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. ⁵³ ⁶²	Andersson S...Wallin KL	16343183	2005
14	Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. ⁵³ ⁶²	Suzuki Y...Oka K	15337561	2004
15	The role of the preoperative serum carcinoembryonic antigen level in early-stage adenocarcinoma of the uterine cervix. ⁵³ ⁶²	Tsai CC...Chien CC	15297173	2004
16	P16 as a molecular biomarker of cervical adenocarcinoma. ⁵³ ⁶²	Schorge JO...Ashfaq R	15041997	2004
17	Correlation between MUC5AC expression and the prognosis of patients with adenocarcinoma of the uterine cervix. ⁵³ ⁶²	Mitsuhashi A...Sekiya S	14699032	2004
18	Primary cervical adenocarcinoma with intestinal differentiation and colonic carcinoma metastatic to cervix: an investigation using Cdx-2 and a limited immunohistochemical panel. ⁵³ ⁶²	Raspollini MR...Taddei GL	14632574	2003
19	CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. ⁵³ ⁶²	McCluggage WG...Young RH	12877729	2003
20	Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. ⁵³ ⁶²	Roh J...Lee H	11248419	2001
21	The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. ⁵³ ⁶²	Sonoda K...Nakano H	11104614	2000
22	Clinical value of tumor markers for early detection of recurrence in patients with cervical adenocarcinoma and adenosquamous carcinoma. ⁵³ ⁶²	Tabata T...Hasumi K	11006578	2000
23	Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix. ⁵³ ⁶²	Lu X...Fujii S	10202666	1999
24	Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. ⁵³ ⁶²	Morimura Y...Sato A	9823779	1998
25	Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. ⁵³ ⁶²	Lu X...Fujii S	9635534	1998
26	Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. ⁵³ ⁶²	Sarandakou A...Chryssikopoulos A	9476065	1998
27	[Relationship between nm23-H1 expression and lymph node metastasis and prognosis in cervical cancer]. ⁵³ ⁶²	Huang Y...Yu S	9772433	1997
28	Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. ⁵³ ⁶²	Fichorova RN...Anderson DJ	9314589	1997
29	Molecular characterization of adenocarcinoma of the cervix. ⁵³ ⁶²	Parker MF...Birrer MJ	9038270	1997
30	What is a normal CA125 level? ⁵³ ⁶²	Alagoz T...DiSaia P	8175027	1994
31	Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. ⁵³ ⁶²	Masood S...Wilson WJ	8319181	1993
32	Oestrogen receptor protein and mRNA in adenocarcinoma of the uterine cervix. ⁵³ ⁶²	Ismail SM...Williams ED	1457356	1992
33	Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma. ⁵³ ⁶²	Leminen A	2258083	1990
34	Adenocarcinoma of the uterine cervix. Prognostic significance of pretreatment serum CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen levels in relation to clinical and histopathologic tumor characteristics. ⁵³ ⁶²	Duk JM...Aalders JG	2317761	1990
35	Mucin leakage into the cervical stroma may increase lymph node metastasis in mucin-producing cervical adenocarcinomas. ⁵³ ⁶²	Konishi I...Mori T	2153042	1990
36	Distribution and incidence of atypical glandular lesions in cervical cytology focusing on the association with high-risk human papillomavirus subtypes. ⁶²	Abbas M...Bettendorf O	36419751	2023
37	Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype. ⁶²	Cohen CM...Clarke MA	36455190	2022
38	Convolutional Neural Networks for Classifying Cervical Cancer Types Using Histological Images. ⁶²	Li YX...Wang M	36474087	2022
39	Identification of novel genetic and epigenetic regulators of different tissue types of cervical cancer. ⁶²	Chandra S...Mandal P	36184073	2022
40	Atypical glandular cells and development of cervical cancer: Population-based cohort study. ⁶²	Norman I...Dillner J	36029205	2022
41	Cervical adenocarcinoma admixing with large cell neuroendocrine carcinoma: A rare case report. ⁶²	Xu F...Zhang Y	35778245	2022
42	Pathological classification of desmoplastic reaction is prognostic factor in cervical adenocarcinoma. ⁶²	Akimoto T...Saito T	35876908	2022
43	Oncologic outcomes of patients with FIGO 2014 stage IB-IIA cervical adenocarcinoma who underwent radical surgery. ⁶²	Yuksel D...Turan T	35303151	2022
44	Comparison of the safety between cervical conization and hysterectomy for patients with cervical adenocarcinoma in situ. ⁶²	Liu J...Shen Y	36424703	2022
45	Invasive stratified mucin-producing carcinoma (ISMC) of uterine cervix: description of pathological findings and prognosis factors in a series of 15 Chinese patients. ⁶²	Lin T...He Y	35394200	2022
46	Value of non-Gaussian diffusion imaging with a fractional order calculus model combined with conventional MRI for differentiating histological types of cervical cancer. ⁶²	Zhang A...Chen T	35988835	2022
47	LncRNA MEG3 promotes cisplatin sensitivity of cervical cancer cells by regulating the miR-21/PTEN axis. ⁶²	Du Y...Wei B	36344947	2022
48	Adenocarcinoma of the uterine cervix, gastric-type (GAS): a review of the literature focused on pathology and multimodality imaging. ⁶²	Kerwin CM...Patel NU	36334123	2022
49	Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification. ⁶²	Bae BK...Park W	36368708	2022
50	Immunohistochemical and molecular analysis of an α-fetoprotein-producing cervical adenocarcinoma with clear cell morphology. ⁶²	Kuriyama S...Nasu K	36183278	2022

Sources

Genes for Cervical Adenocarcinoma

Genes related to Cervical Adenocarcinoma (0 elite genes):

(show all 33)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	20.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14501820 18156982 18202755 (more) 16462152 19762530 11499840 9038270 10202666 15041997
2	TMEM54	Transmembrane Protein 54	Protein Coding	20.35	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Gene name (show sections)
3	KRT7	Keratin 7	Protein Coding	20.21	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14632574 19762530
4	KRT20	Keratin 20	Protein Coding	19.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18156982 19762530 14632574
5	CDX2	Caudal Type Homeobox 2	Protein Coding	19.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14632574 18156982 19762530
6	ESR1	Estrogen Receptor 1	Protein Coding	17.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8319181 1457356 12647218 (more) 9028361 9635534 10202666 10727981 17354237
7	RASSF1	Ras Association Domain Family Member 1	Protein Coding	17.02	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17360030 12702579
8	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	16.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18156982 17365826 2317761
9	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	16.44	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	20524403 11248419 11499840 (more) 10202666 15041997
10	CALB2	Calbindin 2	Protein Coding	16.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12877729
11	CEACAM7	CEA Cell Adhesion Molecule 7	Protein Coding	15.8	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2258083 12647218 2153042 (more) 15297173 11112209 11006578 16515605
12	CXCL12	C-X-C Motif Chemokine Ligand 12	Protein Coding	13.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	17355795
13	TP53	Tumor Protein P53	Protein Coding	13.33	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
14	EBAG9	Estrogen Receptor Binding Site Associated Antigen 9	Protein Coding	12.57	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17981616 11104614
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	12.2	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
16	LAMC2	Laminin Subunit Gamma 2	Protein Coding	12.03	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	16343183
17	PGR	Progesterone Receptor	Protein Coding	11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8319181 8144142 9028361 (more) 10727981 17354237
18	CXCR4	C-X-C Motif Chemokine Receptor 4	Protein Coding	10.9	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
19	NME1	NME/NM23 Nucleoside Diphosphate Kinase 1	Protein Coding	9.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9823779 9772433
20	MKI67	Marker Of Proliferation Ki-67	Protein Coding	9.63	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
21	SPINK1	Serine Peptidase Inhibitor Kazal Type 1	Protein Coding	9.61	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
22	MIR362	MicroRNA 362	RNA Gene	9.57	DISEASES inferred ¹⁴ ¹⁴
23	CDKN1B	Cyclin Dependent Kinase Inhibitor 1B	Protein Coding	8.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11499840 10389977
24	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	8.37	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16290001 8175027 9476065
25	KRT8	Keratin 8	Protein Coding	7.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9314589
26	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	7.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	14699032
27	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	7.36	DISEASES inferred ¹⁴
28	MIR9-1	MicroRNA 9-1	RNA Gene	7.15	DISEASES inferred ¹⁴ ¹⁴
29	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	6.82	GeneCards inferred via : Publications (show sections)
30	INSM1	INSM Transcriptional Repressor 1	Protein Coding	6.7	DISEASES inferred ¹⁴
31	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	6.56	Novoseek inferred ⁵³	15337561 11499840 10202666 (more) 15041997
32	PARP1	Poly(ADP-Ribose) Polymerase 1	Protein Coding	6.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17252195
33	MIR15B	MicroRNA 15b	RNA Gene	6.1	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Cervical Adenocarcinoma

Sources

Expression for Cervical Adenocarcinoma

Search GEO for disease gene expression data for Cervical Adenocarcinoma.

Sources

Pathways for Cervical Adenocarcinoma

Pathways related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.61	CDKN1A CXCL12 CXCR4 EBAG9 ESR1 KRAS
2	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.68	PGR LAMC2 KRAS ESR1 CXCL12
3	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.45	TP53 RASSF1 KRAS CDKN2A CDKN1A
4	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.25	CXCL12 CXCR4 ESR1 KRAS
5	Malignant pleural mesothelioma ⁷⁴	12.24	TP53 RASSF1 LAMC2 CXCL12 CDKN2A CDKN1A
6	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.19	PGR ESR1 CDKN2A CDKN1A
7	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.15	CDKN1A ESR1 KRAS PGR TP53
8	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.07	TP53 KRAS CXCR4 CDKN1A
9	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	11.79	PGR KRAS ESR1 CXCL12
10	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.77	TP53 RASSF1 CDKN2A
11	Small cell lung cancer ⁷⁴	11.75	TP53 LAMC2 CDKN1A
12	Burn wound healing ⁷⁴	11.59	TP53 CXCR4 CXCL12
13	AP-1 transcription factor network ⁶¹	11.53	TP53 ESR1 CDKN2A
14	Validated nuclear estrogen receptor alpha network ⁶¹	11.47	PGR ESR1 EBAG9
15	p53 pathway ⁶¹	11.28	TP53 RASSF1 CDKN2A
16	Head and neck squamous cell carcinoma ⁷⁴	11.12	TP53 KRAS CDKN2A CDKN1A
17	TP53 network ⁷⁴ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.73	TP53 CDKN2A CDKN1A
18	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	10.69	PGR ESR1
19	Bladder cancer ⁷⁴	10.62	TP53 RASSF1 KRAS CDKN2A CDKN1A
20	Transcriptional activation of p53 responsive genes ⁶⁶ Show member pathways Transcriptional activation of cell cycle inhibitor p21 ⁶⁶	10.4	CDKN1A TP53
21	lncRNA-mediated mechanisms of therapeutic resistance ⁷⁴	10.23	TP53 CDKN1A

Sources

GO Terms for Cervical Adenocarcinoma

Biological processes related to Cervical Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.67	TP53 ESR1
2	telencephalon cell migration	GO:0022029	9.62	CXCR4 CXCL12
3	response to ultrasound	GO:1990478	9.46	CXCR4 CXCL12
4	signal transduction by p53 class mediator	GO:0072331	9.43	TP53 CDKN1A
5	replicative senescence	GO:0090399	9.43	TP53 CDKN2A CDKN1A
6	Ras protein signal transduction	GO:0007265	9.32	TP53 RASSF1 KRAS CDKN2A CDKN1A